Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

(2022) Caicun Zhou et al.   LANCET ONCOLOGY

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

(2022) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors

(2022) Frank Rojas et al.   Cancers

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

(2022) Mariano Provencio et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer

(2022) Liang Shi et al.   Frontiers in Oncology

Systematic Review of Neoadjuvant Immunotherapy for Patients with Non-Small Cell Lung Cancer

(2021) Christopher Cao et al.   Seminars in Thoracic and Cardiovascular Surgery

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma

(2021) Dijian Shen et al.   Journal of Thoracic Disease

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

(2021) Sacha I. Rothschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

(2020) Annikka Weissferdt et al.   Clinical Lung Cancer

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY

(2020) William D. Travis et al.   Journal of Thoracic Oncology

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

(2020) Shugeng Gao et al.   Journal of Thoracic Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes

(2020) Yun Ling et al.   npj Precision Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

(2018) Matthew J. Bott et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions

(2018) Mizuki Nishino et al.   RADIOLOGY

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma

(2018) Yang Qu et al.   Journal of Thoracic Oncology

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma

(2016) Valerie W. Rusch et al.   Journal of Thoracic Oncology

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

(2013) Jamie E. Chaft et al.   Journal of Thoracic Oncology

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials

(2012) Guillaume Mouillet et al.   Journal of Thoracic Oncology

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

(2012) Apar Pataer et al.   Journal of Thoracic Oncology

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

(2009) Rodrigo Arriagada et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY